| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | -0.082 | 0.02 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | -0.091 | 0.02 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.086 | 0.02 |
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | 0.18 | 0.02 |
| mRNA | CD-1530 | CTRPv2 | pan-cancer | AAC | 0.093 | 0.02 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | -0.08 | 0.02 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | 0.09 | 0.02 |
| mRNA | KHS101 | CTRPv2 | pan-cancer | AAC | 0.089 | 0.02 |
| mRNA | GW-2580 | GDSC1000 | pan-cancer | AAC | -0.082 | 0.02 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.081 | 0.02 |